Avalo Q3 Loss Narrows to $18.9M; $462.8M Cash Funds Operations Into 2029, But Goodwill Impairment Risk Flagged
AVTX is trading near its 52-week low of $6.53 (9.2% above the low).
Summary
Avalo's Q3 net loss narrowed to $18.9M from $30.6M a year ago, and $462.8M of cash and investments funds operations into 2029. The company also warned that the post-quarter drop in its stock price could trigger a goodwill impairment in Q4.
Key Events · Earnings and Guidance · AVTX
-
Q3 Loss Narrows to $18.9M
Third-quarter net loss was $18.9M, or $0.34 per share, versus $30.6M ($2.19) in Q3 2025, helped by a $12.7M favorable swing in the fair value of the AVTX-007 derivative liability and $4.2M of interest income.
-
Cash Runway Into 2029
Cash, cash equivalents and investments totaled $462.8M at September 30, 2026, after the May 2026 offering raised $404.9M net; nine-month operating cash burn was $49.2M.
-
Goodwill Impairment Risk Flagged
Management said the post-quarter decline in the share price, attributed to market conditions and competitor trial readouts, may put the $10.5M goodwill balance at risk of impairment in Q4 2026.
-
$10.0M Lilly Milestone Accrued
The $10.0M development milestone payable to Lilly on first Phase 3 patient dosing is now deemed probable and sits in accrued liabilities, lifting nine-month R&D to $52.5M from $36.8M.
Analysis · AVTX · Life Sciences
The quarter itself improved: net loss fell to $18.9M from $30.6M a year earlier, helped by a $12.7M favorable swing in the non-cash mark-to-market on the AVTX-007 derivative liability and $4.2M of interest income on a much larger investment balance. The balance sheet is the real story. With $462.8M of cash and investments after the May 2026 offering, operations are funded into 2029, removing any near-term financing need. Against that, the company disclosed that the post-quarter decline in its share price, which it attributes to market conditions and competitor trial readouts, may force a goodwill impairment in Q4; the $10.5M goodwill balance is small relative to equity, so this is a headline risk rather than a solvency one. Nine-month operating burn of $49.2M is running well below the prior-year pace on a per-quarter basis, and the $10.0M Lilly Phase 3 milestone is now accrued, so R&D spend steps up from here as abdakibart enters its registrational program.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVTX was trading at $7.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.2M. The 52-week trading range was $6.53 to $24.27. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.